PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.

Abstract The importance of an early reduction of HIV-1 RNA as a marker for positive longer term outcome is still under debate. We investigate whether antiretroviral-experienced patients receiving raltegravir plus etravirine have a higher early reduction of HIV-1 RNA compared with patients receiving raltegravir.
PMID
Related Publications

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial.

Raltegravir and etravirine are active against HIV type 1 group O.

Authors

Mayor MeshTerms
Keywords
Journal Title journal of acquired immune deficiency syndromes (1999)
Publication Year Start




PMID- 28653971
OWN - NLM
STAT- MEDLINE
DA  - 20170627
DCOM- 20170707
LR  - 20170707
IS  - 1944-7884 (Electronic)
IS  - 1525-4135 (Linking)
VI  - 75
IP  - 4
DP  - 2017 Aug 01
TI  - Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in
      Treatment-Experienced Patients Receiving Raltegravir.
PG  - 448-454
LID - 10.1097/QAI.0000000000001435 [doi]
AB  - OBJECTIVE: The importance of an early reduction of HIV-1 RNA as a marker for
      positive longer term outcome is still under debate. We investigate whether
      antiretroviral-experienced patients receiving raltegravir plus etravirine have a 
      higher early reduction of HIV-1 RNA compared with patients receiving raltegravir.
      DESIGN: An observational study of treatment-experienced patients. METHODS: The
      objective is to investigate 349 patients included in a raltegravir resistance
      study. The early outcome is defined as a reduction of HIV-1 RNA at week 8. The
      crude method defines all measurements below the limit of quantification to be
      equal to the limit of quantification provides biased estimates. Such a reduction 
      is censored by the limit of quantification and is subject to selection bias in
      observational studies. RESULTS: The crude method showed a significant higher
      reduction in HIV-1 RNA reduction in patients receiving raltegravir plus
      etravirine compared with patients receiving raltegravir (mean reduction of 2.1
      versus 1.8 log10 copies/mL). However, survival methods adjusted for both
      censoring, due to the limit of quantification, and confounding factors lead to a 
      nonsignificant difference between the 2 treatment groups (mean reduction of 2.8
      versus 2.7 log10 copies/mL). CONCLUSION: Taking into account censoring and
      confounding factors, our study did not demonstrate a higher early reduction of
      HIV-1 RNA in patients receiving raltegravir with versus without etravirine.
FAU - Flandre, Philippe
AU  - Flandre P
AD  - *Sorbonne Universites, UPMC Universite, INSERM UMR-S 1136, Institut Pierre Louis 
      d'epidemiologie et de Sante Publique (IPLESP), Paris, France;
      anddaggerLaboratoire de Virologie AP-HP, Hopital Pitie-Salpetriere, INSERM UMR-S 
      1136, Institut Pierre Louis d'epidemiologie et de Sante Publique (IPLESP), Paris,
      France.
FAU - Marcelin, Anne-Genevieve
AU  - Marcelin AG
FAU - Calvez, Vincent
AU  - Calvez V
CN  - ANRS AC11 Resistance Study Group
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - J Acquir Immune Defic Syndr
JT  - Journal of acquired immune deficiency syndromes (1999)
JID - 100892005
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Pyridazines)
RN  - 0 (RNA, Viral)
RN  - 0C50HW4FO1 (etravirine)
RN  - 43Y000U234 (Raltegravir Potassium)
SB  - IM
SB  - X
MH  - Adult
MH  - Anti-HIV Agents/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active
MH  - Female
MH  - France
MH  - Gene Expression Regulation, Viral/drug effects
MH  - HIV Infections/*drug therapy/epidemiology/virology
MH  - HIV-1/*drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Propensity Score
MH  - Pyridazines/*therapeutic use
MH  - RNA, Viral/*drug effects/metabolism
MH  - Raltegravir Potassium/*therapeutic use
MH  - Viral Load/drug effects
EDAT- 2017/06/28 06:00
MHDA- 2017/07/08 06:00
CRDT- 2017/06/28 06:00
AID - 10.1097/QAI.0000000000001435 [doi]
AID - 00126334-201708010-00010 [pii]
PST - ppublish
SO  - J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):448-454. doi:
      10.1097/QAI.0000000000001435.